Login Register Cart 0
Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Synthesis and Ready to Use Kit Formulation of EDTMP for the Preparation of 177Lu-EDTMP as a Bone Palliation Radiopharmaceutical

Author(s): Guldem Mercanoglu*, Kani Zilbeyaz and Nuri Arslan

Volume 16, Issue 1, 2023

Published on: 23 August, 2022

Page: [38 - 43] Pages: 6

DOI: 10.2174/1874471015666220721095938

open access plus

Abstract

Introduction: With its suitable nuclear decay characteristics and large-scale production feasibility with adequate specific activity, 177Lu is regarded as an excellent radionuclide for developing bone pain palliation agent. Ethylenediamine-tetramethylene phosphonic acid (EDTMP) is a preferred carrier molecule for radiolanthanides, such as 177Lu. The present paper describes the synthesis of EDTMP and the development of a ready-to-use kit for the preparation of 177Lu-EDTMP and its quality control in accordance with the quality and safety criteria required for medicinal use.

Material and Methods: EDTMP was synthesized by a modified Mannich-type reaction, and the structure was characterized using NMR and IR spectroscopy. Optimization of radiolabeling conditions was done with two different salt forms of EDTMP. The labeling yield was checked by paper chromatography with radiation detection. Kit was developed as a lyophilized mixture of EDTMP and sodium bicarbonate in a maximum volume of 5 mL. Labeling efficiency, radionuclidic purity, radiochemical purity, sterility, and pyrogenicity analysis were performed as the quality control of the labeled kit.

Results: The analytical data for the structure determination and purity of the synthesized ligand were in agreement with authentic commercial samples used in radiopharmacy.177Lu-EDTMP complex was prepared using synthesized EDTMP ligand under optimized labeling conditions with high labelling yield (>99%). The radiolabeling yields of the EDTMP kit at room temperature after 30 min and 48 hours were 99.46% and 99.00%.

Conclusion: The developed EDTMP kit enables an instant one-step preparation of the radiopharmaceutical of high radiochemical purity (>99%) and has a sufficiently long shelf life. This enables the routine production of the 177Lu-EDTMP in nuclear medicine clinics without requiring experienced staff.

Keywords: Bone palliation, EDTMP, 177Lu-EDTMP, ready-to-use kit, radiopharmaceuticals.

« Previous Next »
Graphical Abstract

[1]
Maini, C.L.; Bergomi, S.; Romano, L.; Sciuto, R. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31(Suppl. 1), S171-S178.
[http://dx.doi.org/10.1007/s00259-004-1540-y] [PMID: 15127241]
[2]
Hoskin, P.J. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat. Rev., 2003, 29(4), 321-327.
[http://dx.doi.org/10.1016/S0305-7372(03)00013-6] [PMID: 12927572]
[3]
Pandit-Taskar, N.; Batraki, M.; Divgi, C.R. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J. Nucl. Med., 2004, 45(8), 1358-1365.
[PMID: 15299062]
[4]
Hosain, F.; Spencer, R.P. Radiopharmaceuticals for palliation of metastatic osseous lesions: Biologic and physical background. Semin. Nucl. Med., 1992, 22(1), 11-16.
[http://dx.doi.org/10.1016/S0001-2998(05)80152-7] [PMID: 1375399]
[5]
Volkert, W.A.; Hoffman, T.J. Therapeutic radiopharmaceuticals. Chem. Rev., 1999, 99(9), 2269-2292.
[http://dx.doi.org/10.1021/cr9804386] [PMID: 11749482]
[6]
Bouchet, L.G.; Bolch, W.E.; Goddu, S.M.; Howell, R.W.; Rao, D.V. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J. Nucl. Med., 2000, 41(4), 682-687.
[PMID: 10768569]
[7]
Goddu, S.M.; Bishayee, A.; Bouchet, L.G.; Bolch, W.E.; Rao, D.V.; Howell, R.W. Marrow toxicity of 33P-versus 32P-orthophosphate: Implications for therapy of bone pain and bone metastases. J. Nucl. Med., 2000, 41(5), 941-951.
[PMID: 10809212]
[8]
Chakraborty, S.; Das, T.; Unni, P.R.; Sarma, H.D.; Samuel, G.; Banerjee, S.; Venkatesh, M.; Ramamoorthy, N.; Pillai, M.R.A. 177Lu labelled polyaminophosphonates as potential agents for bone pain palliation. Nucl. Med. Commun., 2002, 23(1), 67-74.
[http://dx.doi.org/10.1097/00006231-200201000-00011] [PMID: 11748440]
[9]
Pillai, M.R.A.; Chakraborty, S.; Das, T.; Venkatesh, M.; Ramamoorthy, N. Production logistics of 177Lu for radionuclide therapy. Appl. Radiat. Isot., 2003, 59(2-3), 109-118.
[http://dx.doi.org/10.1016/S0969-8043(03)00158-1] [PMID: 12941498]
[10]
Sola, G.A.R.; Arguelles, M.G.; Bottazzini, D.L.; Furnari, J.C.; Parada, I.G.; Rojo, A.; Ruiz, H.V. Lutetium-177 EDTMP for bone pain palliation. Preparation, biodistribution and preclinical studies. Radiochim. Acta, 2008, 157-161.
[11]
Mukherjee, A. An update on extemporaneous preparation of radiopharmaceuticals using freeze-dried cold kits. Mini Rev. Med. Chem., 2021, 21(11), 1322-1336.
[http://dx.doi.org/10.2174/1389557520999201214233634] [PMID: 33319668]
[12]
Shinto, A.S.; Shibu, D.; Kamaleshwaran, K.K.; Das, T.; Chakraborty, S.; Banerjee, S.; Thirumalaisamy, P.; Das, P.; Veersekar, G. 1× ×Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases. J. Nucl. Med. Technol., 2014, 42(1), 55-61.
[http://dx.doi.org/10.2967/jnmt.113.132266] [PMID: 24503346]
[13]
Thapa, P.; Nikam, D.; Das, T.; Sonawane, G.; Agarwal, J.P.; Basu, S. Clinical efficacy and safety comparison of 177Lu-EDTMP with 153Sm-EDTMP on an equidose basis in patients with painful skeletal metastases. J. Nucl. Med., 2015, 56(10), 1513-1519.
[http://dx.doi.org/10.2967/jnumed.115.155762] [PMID: 26315829]
[14]
Agarwal, K.K.; Singla, S.; Arora, G.; Bal, C. (177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: A phase II study. Eur. J. Nucl. Med. Mol. Imaging, 2015, 42(1), 79-88.
[http://dx.doi.org/10.1007/s00259-014-2862-z] [PMID: 25070686]
[15]
Mehri, M.; Chafai, N.; Ouksel, L.; Benbouguerra, K.; Hellal, A.; Chafaa, S. Synthesis, electrochemical and classical evaluation of the antioxidant activity of three a-aminophosphonic acids: Experimental and theoretical investigation. J. Mol. Struct., 2018, 1171, 179-189.
[http://dx.doi.org/10.1016/j.molstruc.2018.05.074]
[16]
Elboga, U.; Kilbas, B.; Sahin, E.; Cayırlı, Y.B.; Eryilmaz, K.; Begec, T.; Bakar, H.E.; Mercanoglu, G.; Celen, Y.Z. An automated synthesis of 177Lu-EDTMP as an efficient bone-seeking therapeutic radiopharmaceutical. Eur. Rev. Med. Pharmacol. Sci., 2021, 25(14), 4829-4834.
[PMID: 34337731]
[17]
Garnuszek, P.; Pawlak, D.; Licińska, I.; Kamińska, A. Evaluation of a freeze-dried kit for EDTMP-based bone-seeking radiopharmaceuticals. Appl. Radiat. Isot., 2003, 58(4), 481-488.
[http://dx.doi.org/10.1016/S0969-8043(03)00057-5] [PMID: 12672628]
[18]
Satpati, D. Recent breakthrough in 68Ga-radiopharmaceuticals cold kits for convenient PET radiopharmacy. Bioconjug. Chem., 2021, 32(3), 430-447.
[http://dx.doi.org/10.1021/acs.bioconjchem.1c00010] [PMID: 33630583]
[19]
Choong, K.K.; Ali, M.R.; Talib, Y.; Yen, N.; Hamid, S.A.; Saedon, M.; Kasbollah, A.; Rahim, R.A.; Moktar, M.H.; Kamal, W.H.B. Formulation and quality control studies of edtmp freeze-dried kit for the preparation of 153Sm-EDTMP. AIP Conf. Proc., 2020, 2295, 020008.
[http://dx.doi.org/10.1063/5.0031495]
[20]
Garnuszek, P.; Pawlak, D.; Licinska, I. EDTMP chelates with different radionuclides. Part I. Preparation and investigation of EDTMP chelates with: 153Sm, 177Lu, 99mTc, 51Cr, 113mIn, and 64Cu. Polish Probl Med Nucl, 2001, 15, 71-79.
[21]
Abbasi, I.A. Studies on the labeling of Ethylenediaminetetramethylene phosphonic acid, Methylene Diphosphonate, Sodium pyrophosphate and Hydroxyapatite with Lutetium-177 for use in nuclear medicine. World J. Nucl. Med., 2015, 14(2), 95-100.
[http://dx.doi.org/10.4103/1450-1147.155752] [PMID: 26097419]

Rights & Permissions Print Cite
Article Metrics
70
2
© 2024 Bentham Science Publishers | Privacy Policy